SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update
JERSEY CITY, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the third quarter ended on September 30, 2022.
Related news for (SCYX)
- SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
- SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
- SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
- scynexis to present preclinical data on second generation fungerp scy-247 at idweek 2024
- SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference